R K Shields
Overview
Explore the profile of R K Shields including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
712
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li H, Oliver A, Shields R, Kamat S, Stone G, Estabrook M
Antimicrob Agents Chemother
. 2024 Sep;
68(10):e0067024.
PMID: 39254297
Ceftazidime-avibactam (CZA) and ceftolozane-tazobactam (C/T) are important agents for treating multidrug-resistant infections. In this study, we evaluated the molecular characteristics of 300 globally collected clinical isolates non-susceptible (NS) to CZA,...
2.
Alsenani T, Viviani S, Kumar V, Taracila M, Bethel C, Barnes M, et al.
Antimicrob Agents Chemother
. 2022 Mar;
66(4):e0241421.
PMID: 35341315
Klebsiella pneumoniae carbapenemases (KPC-2 and KPC-3) present a global clinical threat, as these β-lactamases confer resistance to carbapenems and oxyimino-cephalosporins. Recent clinically identified KPC variants with substitutions at Ambler position...
3.
Biagi M, Butler D, Tan X, Qasmieh S, Tejani K, Patel S, et al.
Antimicrob Agents Chemother
. 2019 Sep;
63(12).
PMID: 31527035
The pharmacokinetics (PK) and dialytic clearance of isavuconazole in vitro and in 7 solid organ transplant patients undergoing continuous renal replacement therapy (CRRT) were evaluated. In vivo, mean (± SD)...
4.
Wenzler E, Lee M, Wu T, Meyer K, Shields R, Nguyen M, et al.
J Antimicrob Chemother
. 2018 Dec;
74(3):633-638.
PMID: 30534964
Objectives: To ensure the accuracy of susceptibility testing methods for ceftazidime/avibactam. Methods: The performances of the Etest (bioMérieux), 30/20 μg disc (Hardy diagnostics) and 10/4 μg disc (Mast Group) were...
5.
Espinel-Ingroff A, Arendrup M, Canton E, Cordoba S, Dannaoui E, Garcia-Rodriguez J, et al.
Antimicrob Agents Chemother
. 2016 Nov;
61(1).
PMID: 27799206
Method-dependent Etest epidemiological cutoff values (ECVs) are not available for susceptibility testing of either Candida or Aspergillus species with amphotericin B or echinocandins. In addition, reference caspofungin MICs for Candida...
6.
Dudley-Javoroski S, Petrie M, McHenry C, Amelon R, Saha P, Shields R
Osteoporos Int
. 2015 Sep;
27(3):1149-1160.
PMID: 26395887
Summary: This study examined the effect of a controlled dose of vibration upon bone density and architecture in people with spinal cord injury (who eventually develop severe osteoporosis). Very sensitive...
7.
Eschenauer G, Kwak E, Humar A, Potoski B, Clarke L, Shields R, et al.
Am J Transplant
. 2014 Nov;
15(1):180-9.
PMID: 25359455
Guidelines recommend targeted antifungal prophylaxis for liver transplant (LT) recipients based on tiers of risk, rather than universal prophylaxis. The feasibility and efficacy of tiered, targeted prophylaxis is not well...
8.
Johnson L, Shields R, Clancy C
Transpl Infect Dis
. 2014 Jun;
16(4):578-87.
PMID: 24962102
Background: Few studies of Scedosporium infections following solid organ transplantation have been performed in the era of induction immunosuppression and widespread antifungal prophylaxis. Methods: We performed a single-center, retrospective study...
9.
Clancy C, Bartsch S, Nguyen M, Stuckey D, Shields R, Lee B
Eur J Clin Microbiol Infect Dis
. 2014 Feb;
33(6):1053-61.
PMID: 24500598
Our objective was to model the cost-effectiveness and economic value of routine peri-operative Staphylococcus aureus screening and decolonization of lung and heart-lung transplant recipients from hospital and third-party payer perspectives....
10.
Clancy C, Chen L, Shields R, Zhao Y, Cheng S, Chavda K, et al.
Am J Transplant
. 2013 Sep;
13(10):2619-33.
PMID: 24011185
We conducted a retrospective study of 17 transplant recipients with carbapenem-resistant Klebsiella pneumoniae bacteremia, and described epidemiology, clinical characteristics and strain genotypes. Eighty-eight percent (15/17) of patients were liver or...